CPA Letter to Secretary of Defense Austin Regarding Urgent Updates Needed to List of Chinese Companies Subject to U.S. Capital Markets Sanctions

CPA sent the following letter to U.S. Secretary of Defense Lloyd J. Austin III regarding urgent updates that are needed to the 1260H Chinese Military Companies (CMCs) List and the inclusion of all CMCs on the OFAC NS-CMIC List to limit U.S. funding of China’s People’s Liberation Army. Dear Secretary Austin: Last week, General Milley…

CPA Letter to Treasury Secretary Janet Yellen Regarding China 301 Tariffs

CPA sent the following letter to U.S. Treasury Secretary Janet Yellen regarding her remarks that “lowering some tariffs in a reciprocal way” on China is “a desirable outcome” that could help ease inflation. In the letter, CPA outlines that there is no evidence suggesting that our 301 tariffs on merchandise from China are driving inflation.…

CPA Applauds Efforts to Prevent Stateless Multinational Corporations from Gaming U.S. Corporate Tax System

WASHINGTON — The Coalition for a Prosperous America (CPA) today released a statement on legislative efforts to resolve multinational tax avoidance that plagues the U.S. Treasury and puts U.S. domestic companies at a significant disadvantage to multinational competitors. Specifically, CPA supports reforms to the U.S. corporate tax system that prohibit tax avoidance through the book…

Expert Congressional Testimony Confirms: Congress Must End China’s Exploitation of U.S. Capital Markets, Protect U.S. Investors

WASHINGTON — The Coalition for a Prosperous America (CPA) today submitted written testimony following a hearing in the House Financial Services Subcommittee on Investor Protection, Entrepreneurship, and Capital Markets titled, “Taking Stock of China, Inc.: Examining Risks to Investors and the U.S. Posed by Foreign Issuers in U.S. Markets.” CPA National Security Advisor Robby Stephany…

CPA Welcomes Eligibility Review of AGOA Beneficiaries

WASHINGTON — The Coalition for a Prosperous America (CPA) today released a statement following the termination of Ethiopia, Guinea, and Mali from the African Growth and Opportunity Act (AGOA) tariff preference program as of January 1, 2022, absent urgent action to meet statutory eligibility criteria. “CPA welcomes the news that three AGOA beneficiary governments are…

CPA Applauds Brown, Baldwin Letter to USTR Tai Urging Support of U.S. PPE Production & to End Tariff Exclusions on Chinese PPE

WASHINGTON — The Coalition for a Prosperous America (CPA) today applauded U.S. Senators Sherrod Brown (D-OH) and Tammy Baldwin (D-WI) for leading a letter to United States Trade Representative (USTR) Katherine Tai requesting that 301 penalty duties be assessed to all imported finished state personal protective equipment (PPE) and key raw material inputs, including single-use…

CPA Urges USTR Tai Not to Expand 301 Tariff Exclusions on Chinese Imports

WASHINGTON — The Coalition for a Prosperous America (CPA) today urged U.S. Trade Representative Katherine Tai to not expand exclusions to Chinese imports subject to Section 301 tariffs. Currently, the Biden administration is reviewing 549 products currently subject to 301 tariffs imposed on Chinese imports. CPA strongly supports the current 301 tariffs on Chinese imports…

Generic Drug Shortages and How a Race to the Bottom in Price has Upended 30 years of Hatch-Waxman

CPA’s report, titled “Generic Drug Shortages and How a Race to the Bottom in Price has Upended 30 years of Hatch-Waxman,” details how a loophole in the Hatch-Waxman Act has led to generic drug shortages in the U.S., offshoring of America’s domestic production of generic pharmaceuticals to China and India, and price gouging by foreign…

New CPA Report Documents How Hatch-Waxman Act Loophole Led to Offshoring of Generics Production, Price Gouging, and Shortages

WASHINGTON — The Coalition for a Prosperous America (CPA) today released a new academic report that details how a loophole in the Hatch-Waxman Act has led to generic drug shortages in the U.S., offshoring of America’s domestic production of generic pharmaceuticals to China and India, and price gouging by foreign companies in the U.S. The…